Breast Cancer

Chemotherapy Can Be Spared in Many Patients with Early Breast Cancer: Devil Is in the Details

Phoebe Starr

August 2018, Vol 8, No 8 - Breast Cancer

One of the most important studies presented at ASCO 2018 showed that endocrine therapy alone was noninferior to endocrine therapy plus chemotherapy in women with estrogen receptor (ER)-positive, HER2-negative, node-negative early-stage breast cancer and an intermediate risk score (score, 11-25) on the Oncotype DX gene-expression assay for breast cancer. [ Read More ]

Acquired HER2 Mutations in Metastatic Breast Cancer Confer Resistance to ER-Directed Therapy

Phoebe Starr

June 2018, Vol 8, No 6 - Breast Cancer

Metastatic estrogen receptor (ER)-positive breast cancer responds well to anti-ER therapies, but eventually resistance occurs and the drugs fail to work. A new study presented at the 2018 AACR meeting suggests that HER2 mutations can be acquired during metastatic cancer and their development represents a previously unreported mechanism of resistance to treatment. This resistance can be overcome by the irreversible HER2 inhibitor neratinib (Nerlynx). [ Read More ]

Verzenio (Abemaciclib) a New CDK4/CDK6 Inhibitor Approved for HR-Positive, HER2-Negative Advanced or Metastatic Breast Cancer

Loretta Fala

2018 Third Annual Oncology Guide to New FDA Approvals - Breast Cancer, FDA Approvals, News & Updates

Breast cancer affects more women than any other type of cancer, and represents 15% of all new cancer cases in the United States. A total of 252,710 new breast cancer cases were estimated to be diagnosed in 2017, and more than 40,600 deaths. The prognosis worsens for patients with locally advanced breast cancer and even more so for those with metastatic disease. [ Read More ]

Kisqali (Ribociclib): Second CDK4/CDK6 Inhibitor Approved for Postmenopausal Women with HR-Positive, HER2-Negative Advanced Breast Cancer

Lisa A. Raedler, PhD, RPh

2018 Third Annual Oncology Guide to New FDA Approvals - Breast Cancer, FDA Approvals, News & Updates

Breast cancer is one of the most common cancer diagnoses in the United States. The National Cancer Institute estimates that 252,710 American women will be diagnosed with breast cancer and 40,610 will die from the disease in 2017. For the majority (62%) of women with breast cancer, the disease is confined to the breast, and the 5-year survival approaches 100%. However, for women with metastatic disease, the likelihood of survival at 5 years drops to 27%. [ Read More ]

CDK4/CDK6 Inhibitors Effective in Older Women, but Have More Side Effects

Phoebe Starr

February 2018, Vol 8, No 2 - Breast Cancer, SABCS 2017

Older patients with hormone receptor–positive, HER2-­negative, metastatic breast cancer derive similar benefit as younger patients who received cyclin-dependent kinase (CDK)4/CDK6 inhibitors as part of their initial endocrine therapy, according to a pooled analysis of clinical trials presented at the 2017 San Antonio Breast Cancer Symposium. [ Read More ]